Abstract:Background Candida species are commonly detected as colonizers of the oral cavity; candidiasis or candidemia can develop in patients who are immunocompromised. Use of topical or inhaled glucocorticoids can alter the spectrum of Candida species and can promote oral candidiasis. The present study aims to evaluate the diversity of Candida species in the oral cavity and their susceptibility to antifungal agents in patients undergoing treatment with systemic glucocorticoids (SGCs) compared with non-users. Methods We conducted a descriptive, analytical, cross-sectional study that enrolled 120 patients with oral problems who were undergoing treatment with SGCs and who were admitted to the hospital of the First Affiliated Hospital, College of Medicine, Zhejiang University and Zhejiang Hospital, Hangzhou, China, between February 2019 and September 2019. One hundred and twenty age-and sex-matched patients were recruited as the SGC non-user control group. Demographic data included oral complaints and underlying diseases; symptoms of oral candidiasis were identified on physical examination. Candida species were collected using a concentrated oral rinse. Identification of fungal isolates was based on conventional phenotypic methods assisted by DNA sequence analysis of the internal transcribed spacer (ITS) rDNA gene region. Antifungal activities of anidulafungin, amphotericin B, micafungin, caspofungin, 5-flucytosine, posaconazole, voriconazole, itraconazole, and fluconazole were evaluated using the Sensititre YeastOneTM YO10 panel supplemented by the CLSI-M27-A3 protocol. Results Fifty-two (43.33%) out of the 120 patients undergoing with SGCs were diagnosed with oral candidiasis, compared with 14 (11.67%) of the non-users (P < 0.05). Likewise, we collected 88 strains from 73.33% of the SGC users compared with only 48 (40%) from non-users (P < 0.05). Candida albicans was detected most frequently in both groups (45.45% vs 66.67%, respectively; P = 0.033); the overall frequency of non-Candida albicans (NCA) strains isolated from patients treated with SGCs were significantly higher than that identified among non-users (51.14% vs 33.33%, respectively; P = 0.046), although there were no significant differences concerning any single species of NCA. Resistance of C. albicans to itraconazole (P = 0.004) and fluconazole (P = 0.001) was significantly higher in patients treated with SGCs than in non-users; however, echinocandins, amphotericin B, voriconazole, and posaconazole were all active against strains from both participant groups with no significant differences detected. Conclusion Taken together, our findings indicate that SGC therapy may result in an increased prevalence of oral candidiasis as reflected by the clinical presentations and strains isolated; these findings were also associated with an increased frequency of NCA strains. SGC therapy was also associated with an increased frequency of C. albicans strains that were resistant to both itraconazole and fluconazole. The impact of SGC therapy on Candida species in the oral cavity requires further study.

Fluconazole Susceptibility and Genotypic Heterogeneity of Oral Candida Albicans Colonies from the Patients with Cancer Receiving Chemotherapy in China

Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: an Update from the CHIF-NET Study

Oral Prevalence of Candida Species in Patients Undergoing Systemic Glucocorticoid Therapy and the Antifungal Sensitivity of the Isolates

Distribution and Genotypic Subgroup of Oral Saccharomyces Albicans Isolated from Cancer Patients Receiving Chemotherapy

Genetic and Phenotypic Characterization of Candida Albicans Strains Isolated from Infectious Disease Patients in Shanghai.

Genetic diversity in Fluconazole-resistant and -susceptible oral Candida albicans isolated from patients with Sjgren's syndrome

Genotyping and Antifungal Susceptibility of Candida Albicans Isolates from AIDS Patients

Genotyping and Drug Resistance Profile of Clinical Isolates of Candida Albicans from Vulvovaginal Candidiasis in the Eastern China

Molecular Differentiation and Antifungal Susceptibility of Candida Albicans Isolated from Patients with Respiratory Infections in Guiyang Medical College Hospital, China.

[Antifugal susceptibility testing and antifugal traditional Chinese medicines screening of oral Candida isolated from head and neck cancer patients treated with radiotherapy or chemotherapy]

Antifungal Susceptibility Testing of Commensal and Pathogenic Clinical Isolates of Oral Candida

Drug resistance and genotypes of oral Candida albicans and expressions of drug-resistant genes of oral Candida albicans

Antifungal Susceptibility and Genotypes of Candida Albicans Strains from Patients with Vulvovaginal Candidiasis

Invasive Candidiasis in Intensive Care Units in China: in Vitro Antifungal Susceptibility in the China-SCAN Study

Oral candidiasis fl ora distribution and antifungal susceptibility test in vitro studies

Species distribution and antifungal susceptibility of Candida sp. isolates from AIDS patients with oropharyngeal candidiasis

[Antifungal Susceptibility Test of Genotypes of Candida Albicans from Patients with Atrophic or Erosive Oral Lichen Planus].

Mechanisms of Azole Resistance in Candida Albicans Clinical Isolates from Shanghai, China

Virulence and Antifungal Susceptibility of Microsatellite Genotypes of Candida Albicans from Superficial and Deep Locations

Genotyping of Candida albicans based on 25S rDNA and its relationship to drug susceptibility

Genotyping of Candida Albicans from Maligant Tumor Patients with Deep Candida Albicans Infection